Team Work Matters: Dual Inhibition Puts Non-Hodgkin Lymphoma Under Siege
نویسندگان
چکیده
منابع مشابه
Team work matters: dual inhibition puts non-hodgkin lymphoma under siege.
Inhibitors of PI3K/mTOR and histone deacetylases (HDAC) are effective in non-Hodgkin lymphoma (NHL). However, clinical resistance eventually ensues and combinatory therapies are sought to prevent it. Preclinical evaluation of dual PI3K/mTOR and HDAC inhibition is synergistic against NHL, paving the way for bench-to-bedside translation.
متن کاملHodgkin Lymphoma and Anaplastic Variants of Non-Hodgkin Lymphoma
Background and Objectives: Classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) and some cases of diffuse large B cell lymphoma (DLBCL) have overlapping morphologic features. Since they all represent distinct clinico-pathologic entities, we explored the differential diagnostic impact of immunophenotyping to discriminate between them. Materials and Methods:...
متن کاملNON-HODGKIN\'S LYMPHOMA IN IRAN
Two hundred and ninety cases of non-Hodgkin's lymphoma from the Fars Province Cancer Registry and Mashad University Hospital were reviewed and classified according to the new International Working Formulation for clinical use. The cases fall into low-grade (35 male, 26 female), intermediate-grade (61 male, 26 female), and high-grade (84 male, 26 female) groups. Each group includes several ...
متن کاملNon-Hodgkin Lymphoma (NHL) in Pakistan
Lymphomas are classified as Hodgkin’s and Non-Hodgkin’s lymphomas (HL NHL) NHL being further sub-divided into B, T and Null cell categories on the basis of WHO classification. With a few exceptions worldwide, B-NHL are more common, accounting approximately 80-85% of all cases of NHL compared to T-NHL, which accounts for about 10-15% of all NHL cases. The incidence of NHL has shown a steady incr...
متن کاملDual inhibition of the PI3K/mTOR and MAPK pathways in Non-Hodgkin Lymphoma
DISCLAIMER: The ideas and opinions expressed in the journal’s Just Accepted articles do not necessarily refl ect those of Informa Healthcare (the Publisher), the Editors or the journal. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in these articles. The reader is advised to check...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2014
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-14-2055